CD105 Antibody, anti-human,
REAlease
^®

Name: CD105 Antibody, anti-human, REAlease®
Availability: InStock

CD105 Antibody, anti-human,
REAlease
^®
Extended ValidationRecombinant

Clone:

REAL218

Type of antibody:

Releasable antibodies, Primary antibodies, Recombinant antibodies

Applications:

FC, MICS, IF, IHC

Alternative names:

ENG, END, HHT1, ORW1, Endoglin

Flow cytometry applications forCD105 Antibody, anti-human,
REAlease
^®

FITC
PerCP

Conjugate:

FITC

Recommended dilution:

1:50

Tested:

QC tested

Products used:

130-115-290, 130-115-182, 130-122-631

Protocols:

Cell surface staining protocol using REAlease™ antibodies

Description:

Human Umbilical Vein Endothelial Cells (HUVEC) were stained with REAlease CD105-FITC (B) or with the corresponding REAL Control (A). REAlease CD105-FITC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD105-FITC (D). Cells were and analyzed by flow cytometry using the MACSQuant^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

MICS (MACSima Imaging Cyclic Staining) applications forCD105 Antibody, anti-human,
REAlease
^®

FITC

Conjugate:

FITC

Recommended dilution:

1:30

Fixation:

PFA

Tested:

during development

Species tested:

human

Products used:

130-115-290, 130-115-182

Tissue used:

tonsil

Compatible applications:

IF, IHC

Protocols:

Protocol for MICS experiments

Description:

Immunofluorescence analysis of a human tonsil cryosection fixed with 4% PFA. The section was stained using CD105 Antibody, anti-human, FITC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Conjugate:

FITC

Recommended dilution:

1:30

Fixation:

Acetone

Tested:

during development

Species tested:

human

Products used:

130-115-290, 130-115-182

Tissue used:

tonsil

Compatible applications:

IF, IHC

Protocols:

Protocol for MICS experiments

Description:

Immunofluorescence analysis of a human tonsil cryosection fixed with ice-cold acetone. The section was stained using CD105 Antibody, anti-human, FITC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Extended validation for CD105 Antibody, anti-human,
REAlease
^®

Sensitivity

Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation

Post fixation

Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD105 Antibody, anti-human,
REAlease
^®

Overview

Clone REAL218 is an antibody fragment derived from the full CD105 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL218 recognizes the CD105 antigen, also known as endoglin, which serves as a receptor for the growth and differentiation factors TGF-β1 and TGF-β3. An epitope of CD105 is recognized by the SH-2 antibody, which was raised against human mesenchymal stromal cells (MSC) that show mesodermal differentiation capacity. Therefore, it can be used for studies on mesengenesis. CD105 is also expressed on mature endothelial cells and on some leukemic cells of B lymphoid and myeloid origin.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

ENG, END, HHT1, ORW1, Endoglin

Detailed product information

Technical specifications

Clone	REAL218
Clonality	monoclonal
Isotype control	Control Antibody
Host	human cell line
Type of antibody	Releasable antibodies, Primary antibodies, Recombinant antibodies
Species	human
Antigen	CD105
Alternative names of antigen	ENG, END, HHT1, ORW1, Endoglin
Distribution of antigen	endothelial cells, B cells, myeloid cells
RRID	AB_2751248, AB_2783903, AB_2819672, AB_2819671, AB_2751254

Resources for CD105 Antibody, anti-human,
REAlease
^®

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for CD105 Antibody, anti-human,
REAlease
^®

Publications

Bellón, T. et al. (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23(9): 2340-2345
Barry, F. P. et al. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265: 134-139
Majumdar, M. K. et al. (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J. Cell. Physiol. 185: 98-106

Applications

Extended validation